AN2 Therapeutics, Inc.
ANTX · XNASCIK 1880438fmd_0JS309QZKRQTPK60TY3Y9R8YYTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 23 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | 16 | 29 | 55 | 40 | 25 |
| Total operating expenses | 22 | 42 | 70 | 57 | 38 |
| Operating income | (22) | (42) | (70) | (57) | (38) |
| Interest and investment income | – | – | 5 | 5 | 3 |
| Other non-operating income (expense) | (0) | 1 | 0 | 0 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income | (22) | (41) | (65) | (51) | (35) |
| Net income to common shareholders | (28) | (43) | (65) | (51) | (35) |